The volatility ratio for the week is 20.38%, and the volatility levels for the past 30 days are at 14.05% for BOLD. The simple moving average for the past 20 days is -34.62% for BOLD’s stock, with a -42.04% simple moving average for the past 200 days.
Is It Worth Investing in Boundless Bio Inc. (NASDAQ: BOLD) Right Now?
Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 4 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BOLD is 14.13M, and at present, short sellers hold a 8.10% of that float. On June 19, 2024, the average trading volume of BOLD was 160.92K shares.
BOLD) stock’s latest price update
The stock of Boundless Bio Inc. (NASDAQ: BOLD) has decreased by -3.08 when compared to last closing price of 6.17.Despite this, the company has seen a loss of -35.14% in its stock price over the last five trading days. businesswire.com reported 2024-06-05 that SAN DIEGO–(BUSINESS WIRE)–Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The fireside chat session is schedul.
Analysts’ Opinion of BOLD
Many brokerage firms have already submitted their reports for BOLD stocks, with Piper Sandler repeating the rating for BOLD by listing it as a “Overweight.” The predicted price for BOLD in the upcoming period, according to Piper Sandler is $20 based on the research report published on April 22, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see BOLD reach a price target of $25. The rating they have provided for BOLD stocks is “Outperform” according to the report published on April 22nd, 2024.
Guggenheim gave a rating of “Buy” to BOLD, setting the target price at $24 in the report published on April 22nd of the current year.
BOLD Trading at -39.81% from the 50-Day Moving Average
After a stumble in the market that brought BOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.76% of loss for the given period.
Volatility was left at 14.05%, however, over the last 30 days, the volatility rate increased by 20.38%, as shares sank -43.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.01% lower at present.
During the last 5 trading sessions, BOLD fell by -35.14%, in comparison to the 20-day moving average, which settled at $8.91. In addition, Boundless Bio Inc. saw -58.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BOLD starting from RA CAPITAL MANAGEMENT, L.P., who purchase 312,500 shares at the price of $16.00 back on Apr 02 ’24. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 1,884,787 shares of Boundless Bio Inc., valued at $5,000,000 using the latest closing price.
ARCH Venture Fund IX, L.P., the 10% Owner of Boundless Bio Inc., purchase 200,000 shares at $16.00 during a trade that took place back on Apr 02 ’24, which means that ARCH Venture Fund IX, L.P. is holding 1,181,766 shares at $3,200,000 based on the most recent closing price.
Stock Fundamentals for BOLD
The total capital return value is set at -0.56.
Based on Boundless Bio Inc. (BOLD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -33.19.
Currently, EBITDA for the company is -53.84 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.54.
Conclusion
To sum up, Boundless Bio Inc. (BOLD) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
